Results 71 to 80 of about 12,502 (244)
Frontiers in PharmacologyObjective: We conducted a systematic review to assess the advantages and disadvantages of levosimendan in patients with sepsis compared with placebo, milrinone, and dobutamine and to explore the clinical efficacy of different concentrations of ...
Ruimin Tan +6 more
semanticscholar +1 more source
Frontiers in Physiology, 2022 Background Patients suffering from chronic heart failure (CHF) show an increased prevalence of sarcopenia. Levosimendan is an effective drug for the treatment of heart failure, but its effect on sarcopenia is still unclear.
Di Wang +10 more
semanticscholar +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
Practical approach to diastolic dysfunction in light of the new guidelines and clinical applications in the operating room and in the intensive care [PDF]
, 2018 There is growing evidence both in the perioperative period and in the field of intensive care (ICU) on the association between left ventricular diastolic dysfunction (LVDD) and worse outcomes in patients.
Morelli, A. +3 more
core +1 more source
Use of Levosimendan in Cardiac Anesthesiology
Общая реаниматология, 2011 The authors consider the main aspects of the rational use of the novel inotropic drug levosimendan in cardiosurgical patients on the basis of the results of the trials described in the literature and on their own findings in this review.
L. A. Krichevsky +4 more
doaj +1 more source
European Journal of PharmacologyHeart failure with preserved ejection fraction (HFpEF) is a syndrome characterized by impaired cardiovascular reserve in which therapeutic options are scarce.
Liliana Moreira-Costa +11 more
semanticscholar +1 more source
Levosimendan increases the phosphorylation state of phospholamban in the isolated human atrium
Naunyn-Schmiedeberg's Archives of Pharmacology, 2022 Levosimendan (up to 10 µM) given alone failed to increase force of contraction in isolated electrically stimulated (1 Hz) left atrial (LA) preparations from wild-type mice.
Lina Maria Rayo Abella +4 more
semanticscholar +1 more source
From Thrombolysis to Transplant: Navigating the Storm of Delayed STEMI and Cardiogenic Shock
Clinical Case Reports, Volume 14, Issue 3, March 2026.ABSTRACT Delayed STEMI presentation can cause extensive myocardial necrosis, left ventricular thrombus, cardiogenic shock, and progression to end‐stage heart failure despite reperfusion. Early recognition and timely transfer to specialized shock centers are critical.
Syed Rafay Hussain Zaidi +8 more
wiley +1 more source
FEBS Open Bio, 2021 ATP‐sensitive potassium channels (KATPs) have protective effects in ischemia–reperfusion‐induced injuries and can be activated by levosimendan. This study investigated the effects of levosimendan on renal injury, inflammation, apoptosis, and survival in ...
Lei Tian +6 more
doaj +1 more source
Levosimendan: Perpetuum mobile? [PDF]
European Heart Journal, 2007 We read with great interest the well-written review about levosimendan by De Luca et al. 1 Levosimendan is certainly an interesting drug that appears to deliver favourable effects in patients with acute heart failure. Numerous studies have demonstrated the positive inotropic …
Stefan, Agewall, Dan, Atar
openaire +2 more sources